Beam Therapeutics shareholders elect directors, ratify Deloitte, approve say-on-pay

Beam Therapeutics Inc.

Elected Mark Fishman (61.9M for, 10.3M against), Carole Ho (71.7M for), and Kathleen Walsh (71.9M for) as Class II directors.
Ratified Deloitte & Touche as independent auditor for FY2025 with 84.3M for, 154K against, 63.6K abstentions.
Advisory vote on named executive officer compensation approved: 71.7M for, 562.9K against, 33.9K abstentions.
All proposals passed; broker non-votes were 12.2M on director elections and say-on-pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.